Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Treatment of mild to moderate metabolic acidosis,Correction of acid-base imbalance in conditions such as diabetic ketoacidosis (as an adjunct),Fluid resuscitation in hypovolemic states when alkalinization is desired (off-label)
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Lactate has a plasma half-life of approximately 5-10 minutes in healthy individuals. In patients with hepatic impairment or shock, half-life may be prolonged to 1-2 hours due to reduced metabolism.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Lactate is metabolized primarily in the liver via lactate dehydrogenase to pyruvate, then enters the gluconeogenesis pathway or the Krebs cycle for oxidation to carbon dioxide and water, generating bicarbonate. Metabolism is dependent on hepatic function.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Sodium lactate is metabolized to bicarbonate primarily in the liver (60-70%) and kidneys (30-40%). Excretion of unmetabolized lactate is minimal (<5%) via urine. Biliary/fecal excretion negligible.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Lactate is not significantly protein-bound (<1%). It is freely filtered and metabolized.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Volume of distribution for lactate is approximately 0.3-0.5 L/kg, reflecting distribution into total body water and rapid cellular uptake.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Only relevant route is intravenous; oral lactate is rapidly metabolized in the liver (first-pass effect), but no IV bioavailability data exists; effectively 100% for IV administration.
100% intravenous; not administered by other routes.
GFR 30-50 m L/min: caution, monitor for volume overload and electrolyte disturbances; GFR <30 m L/min: avoid due to risk of sodium overload and metabolic alkalosis. No specific dose reduction; use with close monitoring.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Child-Pugh A-B: no adjustment; Child-Pugh C: caution due to impaired lactate metabolism; monitor for acidosis/alkalosis.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Neonates and infants: 2-5 m L/kg (0.33-0.83 mmol/kg) intravenously over 1-2 hours; repeated as needed based on acid-base status. Children: 5-10 m L/kg (0.83-1.66 mmol/kg) IV over 1-2 hours. Maximum infusion rate: 5 m L/kg/h.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Start at lower end of adult dose (300 m L) due to decreased renal function and risk of fluid overload; monitor electrolytes and volume status closely.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with impaired liver function, as conversion to bicarbonate may be reduced,Risk of metabolic alkalosis with excessive administration,Should not be used in severe metabolic acidosis (p H < 7.1) or lactic acidosis,Monitor serum electrolytes, p H, and fluid status during administration,Contains sodium; use with caution in patients with congestive heart failure, edema, or renal impairment
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Severe metabolic acidosis (p H < 7.1),Lactic acidosis,Alkalosis,Hypernatremia,Fluid overload states,Severe hepatic failure (inability to convert lactate to bicarbonate),Known hypersensitivity to sodium lactate or any component of the formulation
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No significant food-drug interactions are known. However, patients on sodium-restricted diets should be informed of the sodium content of this solution.
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intravenously for fluid and electrolyte replacement. The risk to the fetus is minimal when used according to standard clinical practice across all trimesters.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Sodium lactate is a normal component of breast milk and is not expected to cause adverse effects. The M/P ratio is not specifically defined but is likely similar to plasma levels. Use during breastfeeding is considered safe.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Standard dosing for fluid and electrolyte replacement is generally appropriate during pregnancy. No specific dose adjustments are typically required, but careful monitoring of volume status and electrolytes is recommended due to potential pregnancy-related changes in renal function and hemodynamics.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Sodium lactate 0.167 Molar is an isotonic crystalloid solution primarily used as a source of bicarbonate precursors in metabolic acidosis. Monitor serum lactate levels to distinguish iatrogenic hyperlactatemia from lactic acidosis. Avoid in patients with severe metabolic alkalosis or hypernatremia. Use with caution in hepatic impairment due to impaired lactate clearance. In cardiac arrest, consider use only if indicated by arterial blood gas; routine use is not recommended.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This intravenous solution provides electrolytes and fluid to help correct body acid imbalance.,Tell your healthcare provider if you have a history of liver disease, kidney problems, or are on a low-sodium diet.,Report any symptoms such as muscle twitching, confusion, or irregular heartbeat during infusion.,You may experience temporary discomfort or swelling at the infusion site.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is an alkalinizing agent that is metabolized to bicarbonate in the liver, increasing plasma bicarbonate concentration and buffering hydrogen ions, thereby correcting metabolic acidosis. The lactate ion is converted to pyruvate and then to glucose or oxidized via the Krebs cycle, yielding bicarbonate.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion; initial dose 300-500 m L (50-83 mmol) administered over 1-2 hours; subsequent doses based on serum bicarbonate and clinical response. Maximum infusion rate: 300 m L/h.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate, as a component of lactated Ringer's solution, is generally considered safe during pregnancy. No teratogenic effects have been reported in humans. It is used intrave. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.